MISSION Therapeutics: Funding, Investors & Team (Sep 2026)
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
MISSION Therapeutics has raised $51.2M across 4 funding rounds on record, the most recent an undisclosed round of $13.3M announced in Oct 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
MISSION Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2025.
MISSION Therapeutics Funding Rounds
MISSION Therapeutics raised $500k in a Grant announced in Oct 2021.
2.4 years later, an undisclosed round of $32.2M was announced in Mar 2024.
4 months later, an undisclosed round of $5.2M was announced in Jul 2024.
1.3 years later, an undisclosed round of $13.3M was announced in Oct 2025.
MISSION Therapeutics Founders and Leadership Team
Contact details for the MISSION Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →MISSION Therapeutics Funding Compared to Other Biotechnology Startups
MISSION Therapeutics' latest round of $13.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like MISSION Therapeutics in Biotechnology and Cambridge
Companies Similar to MISSION Therapeutics
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
MISSION Therapeutics Funding FAQs
What does MISSION Therapeutics do?
Mission Therapeutics is a drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
How much funding has MISSION Therapeutics raised?
MISSION Therapeutics has raised $51.2M across 4 rounds on record. The most recent is an undisclosed round of $13.3M announced in Oct 2025.
When did MISSION Therapeutics last raise funding?
MISSION Therapeutics' most recent funding round on record is an undisclosed round of $13.3M, announced in Oct 2025.
Who founded MISSION Therapeutics?
FundedIQ lists Steve Jackson (Founder) at MISSION Therapeutics.
Who is the CEO of MISSION Therapeutics?
Anker Lundemose is listed as CEO at MISSION Therapeutics.
Where is MISSION Therapeutics headquartered?
MISSION Therapeutics is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does MISSION Therapeutics have?
MISSION Therapeutics is in the 51-100 employee band.
How does MISSION Therapeutics' funding compare to other Biotechnology startups?
MISSION Therapeutics' latest round of $13.3M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's MISSION Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for MISSION Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.